Dermatologists

Pemphigus vulgaris (PV) is a rare autoimmune mucocutaneous blistering disease associated with significant morbidity when not treated promptly. The advent of corticosteroids largely eliminated the mortality risk associated with pemphigus, but exposes patients to risk of bone loss and infection and is contraindicated in some patients. While the rarity of this disease has challenged the development of randomized controlled trials, other agents have shown promise. This interactive web monograph provides an overview of PV and its diagnosis and current treatment as well as data on the safety and efficacy of emerging adjuvant and alternative therapies such as mycophenolate mofetil, intravenous immunoglobulins, rituximab, dapsone, and methotrexate.

The Role of Emerging Therapies in the Management of Pemphigus Vulgaris

 

Chair

Victoria P. Werth, MD
Professor of Dermatology
University of Pennsylvania
Dept. of Dermatology
Perelman Center for Advanced Medicine
Philadelphia, PA

Faculty

Annette Czernik, MD
Assistant Professor of Dermatology
Icahn School of Medicine at Mount Sinai
Department of Dermatology
New York, NY

Dedee Murrell, MD
Professor and Chair
St. George Hospital, University of NSW
Department of Dermatology
St. George Hospital
Sydney, Australia

Target Audience

The activity has been designed to address the educational needs of clinicians specializing in dermatology, including physicians, nurse practitioners, and physician assistants. It may also be of benefit to primary care clinicians and dentists, as well as other clinicians who treat and manage patients with pemphigus vulgaris.

Release Date: April 29, 2016
Last Reviewed: April 20, 2016
Expiration Date: April 29, 2017
Time to Complete Activity: 1.0 hour

This activity is provided by Global Education Group.  Paradigm Medical Communications, LLC is the educational partner.

GlobalLogo Paradigm Logo

Learning Objectives

Upon proper completion of this activity, participants should be better able to:

  • Describe the clinical diagnosis of pemphigus vulgaris.
  • Choose optimal therapy for individual patients with pemphigus vulgaris based on the most current evidence-based data.
  • Evaluate novel safety and efficacy data from clinical trials on current and emerging agents for pemphigus vulgaris.

Physician Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation Statement

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant Continuing Education

The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.  Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

For information about the accreditation of this program, please contact Global at (303) 395-1782 or inquire@globaleducationgroup.com.

Disclosure of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Rheumatologists

Pemphigus vulgaris (PV) is a rare autoimmune mucocutaneous blistering disease associated with significant morbidity when not treated promptly. While most patients are initially treated with glucocorticoids and adjuvant immunosuppressive agents by a dermatologist, some patients are nonresponsive. This interactive web monograph provides an overview of PV and its diagnosis and current treatment as well as data on the safety and efficacy of emerging therapies such as rituximab, dapsone, and methotrexate. Because most dermatologists do not provide infusion therapies, they often confer with rheumatologists, who are better equipped to screen patients for suitability for intravenous infusion of biologics such as rituximab. Rheumatologists therefore need to be aware of their potential role in managing these patients in concert with dermatologists.

Contemporary Management of Pemphigus Vulgaris: The Role of the Rheumatologist

 

Faculty

A. Razzaque Ahmed, MD
Professor of Dermatology, Tufts University School of Medicine
Director, Center for Blistering Diseases
Boston, MA

Yousaf Ali, MD
Vice Chair, Faculty Affairs, Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
Department of Medicine – Division of Rheumatology
New York, NY

Target Audience

The activity has been designed to address the educational needs of clinicians specializing in rheumatology, including physicians, nurse practitioners, and physician assistants. It may also be of benefit to dermatologists, primary care clinicians, and dentists, as well as other clinicians who treat and manage patients with pemphigus vulgaris.

Release Date: May 5, 2016
Last Reviewed: April 20, 2016
Expiration Date: May 5, 2017
Time to Complete Activity:  1.0 hour

This activity is provided by Global Education Group.  Paradigm Medical Communications, LLC is the educational partner.

GlobalLogo Paradigm Logo

Learning Objectives

Upon proper completion of this activity, participants should be better able to:

  • Choose optimal therapy for individual patients with pemphigus vulgaris based on the most current evidence-based data
  • Evaluate safety and efficacy data from clinical trials on current and emerging agents for pemphigus vulgaris

Physician Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation Statement

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant Continuing Education

The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.  Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

For information about the accreditation of this program, please contact Global at (303) 395-1782 or inquire@globaleducationgroup.com.

Disclosure of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.